iRhythm Technologies (IRTC) Wolfe Research Healthcare Conference 2024 summary

Regulatory and quality transformation

• Achieved clearance for two key 510(k) submissions, marking a significant regulatory milestone.

• Implementing a comprehensive transformation of the quality management system, exceeding FDA requirements.

• A 12-month remediation plan is underway, with monthly updates to the FDA and efforts extending through 2025.

• Major focus on integrating qualified technicians into the quality system, updating documentation and processes.

• Hired a new head of quality and engaged a reputable external firm for internal audit and compliance support.

Product development and submission timing

• Delay in next-gen MCT device submission is voluntary, aimed at enhancing robustness, not due to FDA request.

• Timing of the Zio MCT submission is independent of recent 510(k) clearances.

• Zio MCT will extend wear duration to 21 days, offering a competitive upgrade over current AT product.

Market performance and business momentum

• AT product is gaining market share due to patient compliance advantages and strong commercial execution.

• Growth in the MCT segment is attributed to competitive share gains rather than market expansion.

• XT and core business showed strong momentum, with positive trends in new account openings and October performance.

• Seasonal factors, such as summer, impact device wear and revenue timing, but recent quarters finished strong.